New treatment for melanoma patients who can't use immunotherapy
Official title: Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
Funded at Linnaeus Therapeutics INC · NIH-11062612 · Data updated 2026-11-12
This study is testing a new pill called LNS8801 for people with skin cancer who can’t handle current immunotherapy treatments because of bad side effects, aiming to make cancer treatment easier and more effective for those who need better options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Linnaeus Therapeutics INC NIH-funded |
| Lab location | 1 site (Haddonfield, United States) |
| Project start | January 13, 2025 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $999,960 |
| NIH project number | 1R44CA297994-01 |
| Project ID | NIH-11062612 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cutaneous melanoma who have experienced significant side effects from immunotherapy and are seeking alternative treatment options.
✕Less likely to help
Patients with melanoma who are currently responding well to existing immunotherapy treatments may not benefit from this research.
What this research studies
This research focuses on developing a new oral medication called LNS8801 for patients with cutaneous melanoma who are unable to tolerate existing immunotherapy options due to severe side effects. The approach involves targeting a specific receptor in cancer cells to enhance treatment effectiveness while minimizing adverse reactions. By combining LNS8801 with standard cancer therapies, the goal is to improve patient outcomes and provide a well-tolerated alternative for those who have limited options. The research will involve clinical trials to assess the safety and efficacy of this new treatment.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for melanoma patients who cannot tolerate current immunotherapies.
How similar studies have gone: Previous research has shown promise with similar approaches targeting the GPER receptor, indicating potential for success in this novel treatment.
Where this research is happening
-
Linnaeus Therapeutics INC
Haddonfield, United States Active
Researchers
- Principal investigator: Garyantes, Tina — Linnaeus Therapeutics INC
- Study coordinator: Garyantes, Tina
Related research
Other NIH-funded projects on the same topics.
-
LNS8801: a new cancer drug to help advanced melanoma patients who can’t tolerate immunotherapy
A small-molecule drug called LNS8801 is being studied to help people with advanced melanoma who can’t tolerate immunotherapy, by working with standard treatments and aiming for fewer side effects.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Characterizing the psychological symptoms in melanoma patients on immunotherapy
A long-term study follows adults with advanced skin cancer who are starting immune checkpoint therapy to understand the pattern of emotional and psychological symptoms they experience.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
New approach to overcome resistance to immunotherapy in melanoma
A new strategy targets a key pathway in melanoma to boost the effectiveness of immune-based therapies for patients whose cancer resists treatment.
-
Multivalent circular mRNA vaccines for melanoma immunotherapy
A cancer vaccine approach using tiny circular mRNA vaccines aimed at boosting immune responses against melanoma in combination with existing immunotherapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.